Azelaic Acid

Azelaic Acid

SCHEMBL787258

C=CCN1C=NCC1.O=C(O)CCCCCCCC(=O)O

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.43
ABCC4 O15439 1/20 0.43
LMNA P02545 2/20 0.36
TSHR P16473 2/20 0.36
NFKB1 P19838 1/20 0.36
PMP22 Q01453 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
TBXAS1 P24557 4/20 0.33
KMT2A Q03164 1/20 0.33
GPR84 Q9NQS5 2/20 0.32
FFAR1 O14842 1/20 0.32
FFAR4 Q5NUL3 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
PTGS1 P23219 4/20 0.32
PTGS2 P35354 4/20 0.32
ALDH1A1 P00352 1/20 0.32
SLC22A6 Q4U2R8 1/20 0.32
SLC22A8 Q8TCC7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glycine SCHEMBL28316402 0.84 GLRA1 (0.32) NPC1RAB9A
Methane SCHEMBL27830991 0.80
Hydrochloric Acid SCHEMBL1846220 0.80
Methane SCHEMBL28028970 0.78
Bromide SCHEMBL6700096 0.78
Alanine SCHEMBL3261341 0.78
SCHEMBL26547315 0.77 CYP1A2 (0.44) LMNATSHRNFKB1PMP22TBXAS1
SCHEMBL27807839 0.77
SCHEMBL30426268 0.77 ALDH1A1 (0.45) MAPTLMNATSHRKMT2AFFAR1
Thiourea SCHEMBL29031905 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9006316-B2 Organometallic compositions and coating compositions KING INDUSTRIES, INC. (US) 2015-04-14 US claimed
US-20120070569-A1 ORGANOMETALLIC COMPOSITIONS AND COATING COMPOSITIONS KING INDUSTRIES, INC. (US) 2012-03-22 US claimed
US-20090011124-A1 Complexes of zinc with substituted amidines and guanidines and aliphatic carboxylates, e.g., Zn(1-methylimidazole)2(acetate)2 and Zn(1-methylimidazole)2(2-ethylhexanoate)2; useful as catalysts for deblocking blocked isocyanates and in the production of urethanes and polyurethanes HSIEH BING 2009-01-08 US claimed
EP-1778778-A2 ORGANOMETALLIC COMPOSITIONS AND COATING COMPOSITIONS King Industries, Inc. (US) 2007-05-02 EP claimed
US-20060247341-A1 Complexes of zinc with substituted amidines and guanidines and aliphatic carboxylates, e.g., Zn(1-methylimidazole)2(acetate)2 and Zn(tetramethylguanidine)2(formate)2; useful as catalysts for deblocking blocked isocyanates and in the production of urethanes and polyurethanes KING INDUSTRIES, INC. 2006-11-02 US claimed
WO-2006022899-A2 ORGANOMETALLIC COMPOSITIONS AND COATING COMPOSITIONS KING INDUSTRIES, INC. (US) 2006-03-02 WO claimed
US-20060036007-A1 Organometallic compositions and coating compositions KING INDUSTRIES, INC. (US) 2006-02-16 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120070569-A1 ORGANOMETALLIC COMPOSITIONS AND COATING COMPOSITIONS UROD, AOC1, AOC2 MAPT 1072/4885ABCC4 4397/4885LMNA 4431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.